BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23023514)

  • 1. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
    Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
    Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
    Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
    Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
    J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
    Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
    Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of calbindin-D28k expression in lung cancer: analysis of 452 cases.
    Castro CY; Stephenson M; Gondo MM; Medeiros LJ; Cagle PT
    Mod Pathol; 2000 Jul; 13(7):808-13. PubMed ID: 10912942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
    Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
    World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
    Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
    Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
    J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis.
    Berta J; Kenessey I; Dobos J; Tovari J; Klepetko W; Jan Ankersmit H; Hegedus B; Renyi-Vamos F; Varga J; Lorincz Z; Paku S; Ostoros G; Rozsas A; Timar J; Dome B
    J Thorac Oncol; 2010 Aug; 5(8):1120-9. PubMed ID: 20581707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer.
    Guo C; Hao C; Shao R; Fang B; Correa AM; Hofstetter WL; Roth JA; Behrens C; Kalhor N; Wistuba II; Swisher SG; Pataer A
    Oncotarget; 2015 May; 6(13):11114-24. PubMed ID: 25798539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathobiological implications of MUC4 in non-small-cell lung cancer.
    Majhi PD; Lakshmanan I; Ponnusamy MP; Jain M; Das S; Kaur S; Shimizu ST; West WW; Johansson SL; Smith LM; Yu F; Rolle CE; Sharma P; Carey GB; Batra SK; Ganti AK
    J Thorac Oncol; 2013 Apr; 8(4):398-407. PubMed ID: 23370366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
    Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X
    World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
    Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
    Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
    Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
    J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FBXO25 promotes cell proliferation, invasion, and migration of NSCLC.
    Jiang GY; Zhang XP; Wang L; Lin XY; Yu JH; Wang EH; Zhang Y
    Tumour Biol; 2016 Oct; 37(10):14311-14319. PubMed ID: 27596142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
    Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
    J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.